Dance Biopharm signs an agreement with DarioHealth to integrate Dance's gentle mist smart inhaler into DarioHealth's platform allowing for automated, real-time treatment data through a mobile application

A joint venture between Atropos and Atomwise will discover and develop anticancer agents using senescence assay and AI technologies

"Interoperability" – a fancy term for the ability to exchange medical data among health-care providers and institutions – is increasingly important in a technologically advancing age, with medicine becoming the realm of highly specialized diagnosticians and others who rely on applied technology for effective treatment.

Internationally recognized leaders to advise on innovations in pregnancy care for the 21st century

The United States is one of the most dangerous places in the developed world for a black woman giving birth and for black infants in their first year of life.

Harvard-trained, nationally renowned neuropsychiatrist develops Emerging Consciousness Program for children and adults

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC) recently honored six community health centers in the U.S. with the "Innovations in Care" award in recognition of their success in low-resource areas identifying and assisting vulnerable people to better manage complex chronic diseases and improve their health.

According to the American Cancer Society, prostate cancer is the second most common cancer in American men, affecting more than 10 percent of the population.

Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine.

Collaborative program helps CROs deliver additional value to sponsors with best practices for Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions

Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, announced the publication of a new study on Frontiers in Oncology comparing GenesWell™ BCT, a prognostic multigene test, with Genomic Health's Oncotype DX in patients with early-stage breast cancer.

Islam is the second-largest religion in the world and the fastest growing religion in the United States. Certified Registered Nurse Anesthetists (CRNAs) attending the American Association of Nurse Anesthetists (AANA) Annual Congress, August 9-13, 2019, in Chicago will have an opportunity to learn about this religion to help provide culturally competent care to Muslim patients.

Multi-Year Project to Analyze Largest Patient Safety Database in the Country and Use Innovative Approach to More Rapidly Identify Actionable Insights

I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, jointly announced that TRACON has dosed the first patient in a U.S. Phase 1 first-in-human clinical trial of I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors (NCT identifier number: NCT03835949). TJD5 will be dosed in the Phase 1 trial both as a single agent and in combination with TECENTRIQ® (atezolizumab), a PD-L1 antibody marketed by Roche. I-Mab entered into a research collaboration with Roche in April 2019 where Roche agreed to supply TECENTRIQ® to I-Mab for use in clinical study in combination with TJD5.

A spokesperson for the Council for Affordable Health Coverage (CAHC) says that the simplest solution to surprise billing, banning it outright, is the best solution, however the health system lobby is slowing down efforts in Congress to enact such a ban.

New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.

Low-Dose Aspirin Continues to be the Gold Standard Treatment After Having a Heart Attack or Ischemic Stroke

Partnership between Backpack Health and Cure HHT will empower patients and contribute to the advancement of HHT research

Three-week June campaign successfully rallied blood donors to donate A, B, AB and O

Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue